Protective conditioning for acute graft-versus-host disease

被引:246
作者
Lowsky, R
Takahashi, T
Liu, YP
Dejbakhsh-Jones, S
Grumet, FC
Shizuru, JA
Laport, GG
Stockerl-Goldstein, KE
Johnston, LJ
Hoppe, RT
Bloch, DA
Blume, KG
Negrin, RS
Strober, S
机构
[1] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA
[4] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA
关键词
D O I
10.1056/NEJMoa050642
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans. METHODS: Thirty-seven patients with lymphoid malignant diseases or acute leukemia underwent an experimental conditioning regimen with 10 doses of total lymphoid irradiation (80 cGy each) plus antithymocyte globulin, followed by an infusion of HLA-matched peripheral-blood mononuclear cells from related or unrelated donors who received granulocyte colony-stimulating factor. RESULTS: Of the 37 transplant recipients, only 2 had acute GVHD after hematopoietic-cell transplantation. Potent antitumor effects in patients with lymphoid malignant diseases were shown by the change from partial to complete remission. In the transplant recipients who underwent conditioning with total lymphoid irradiation and antithymocyte globulin, the fraction of donor CD4+ T cells that produced interleukin-4 after in vitro stimulation increased by a factor of five, and the proliferative response to alloantigens in vitro was reduced, as compared with normal control subjects and control subjects who underwent conditioning with a single dose of total-body irradiation (200 cGy). CONCLUSIONS: A regimen of total lymphoid irradiation plus antithymocyte globulin decreases the incidence of acute GVHD and allows graft antitumor activity in patients with lymphoid malignant diseases or acute leukemia treated with hematopoietic-cell transplantation.
引用
收藏
页码:1321 / 1331
页数:11
相关论文
共 32 条
[1]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[2]   CD1 RECOGNITION BY MOUSE NK1(+) T-LYMPHOCYTES [J].
BENDELAC, A ;
LANTZ, O ;
QUIMBY, ME ;
YEWDELL, JW ;
BENNINK, JR ;
BRUTKIEWICZ, RR .
SCIENCE, 1995, 268 (5212) :863-865
[3]   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[4]   CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation [J].
Edinger, M ;
Hoffmann, P ;
Ermann, J ;
Drago, K ;
Fathman, CG ;
Strober, S ;
Negrin, RS .
NATURE MEDICINE, 2003, 9 (09) :1144-1150
[5]  
FOWLER DH, 1994, J IMMUNOL, V152, P1004
[6]  
FOWLER DH, 1994, BLOOD, V84, P3540
[7]   Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases [J].
Georges, GE ;
Maris, M ;
Sandmaier, BM ;
Maloney, DG ;
Feinstein, L ;
Niederweiser, D ;
Shizuru, JA ;
McSweeney, PA ;
Chauncey, TR ;
Agura, E ;
Little, MT ;
Sahebi, F ;
Hegenbart, U ;
Pulsipher, MA ;
Bruno, B ;
Forman, S ;
Woolfrey, AE ;
Radich, JP ;
Blume, KG ;
Storb, R .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (Suppl 1) :184-189
[8]   Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation [J].
Giralt, S ;
Thall, PF ;
Khouri, I ;
Wang, XM ;
Braunschweig, I ;
Ippolitti, C ;
Claxton, D ;
Donato, M ;
Bruton, J ;
Cohen, A ;
Davis, M ;
Andersson, BS ;
Anderlini, P ;
Gajewski, J ;
Kornblau, S ;
Andreeff, M ;
Przepiorka, D ;
Ueno, NT ;
Molldrem, J ;
Champlin, R .
BLOOD, 2001, 97 (03) :631-637
[9]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304
[10]   Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation [J].
Hoffmann, P ;
Ermann, J ;
Edinger, M ;
Fathman, CG ;
Strober, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) :389-399